Service was Neuronetics’s largest revenue line in fiscal 2025, bringing in $86.98M of $233.03M (37%).
| Concentration Risk Type | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Service | — | — | $4.45M | $86.98M | |||||
| Clinic Revenue | — | — | $4.45M | $86.98M | |||||
| Treatment Sessions | $45.08M | $50.90M | $50.83M | $43.32M | |||||
| Neurostar Advanced Therapy System | $16.58M | $16.46M | $15.27M | $14.26M | |||||
| Other | $1.75M | $1.98M | $1.94M | $1.49M | |||||
| Total | $63.41M | $69.34M | $76.93M | $233.03M |
Neuronetics brought in $233.03M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 202.9% from $76.93M in fiscal 2024. Service was the largest at $86.98M (37.3%), ahead of Clinic Revenue at $86.98M (37.3%) and Treatment Sessions at $43.32M (18.6%). The other two revenue lines brought in $15.75M combined.
Compared with fiscal 2024, Service grew fastest, up 1,856.7% to $86.98M, while Treatment Sessions fell the most, down 14.8% to $43.32M.
Neuronetics began breaking out Service in fiscal 2024 and Clinic Revenue in fiscal 2024.
U.S was Neuronetics’s largest region in fiscal 2025, bringing in $86.98M of $88.25M (99%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| U.S | $45.08M | $50.90M | $50.83M | $86.98M | |||||
| United States | — | — | — | — | |||||
| International | $811.00K | $2.01M | $963.00K | $1.28M | |||||
| Total | $45.89M | $52.91M | $51.80M | $88.25M |
Neuronetics brought in $88.25M from its two regions in fiscal 2025, the year ended December 31, 2025. That is less than the $233.03M it reports by concentration risk type, so these regions do not cover all of its revenue. U.S was the largest at $86.98M (98.6%), ahead of International at $1.28M (1.4%).
Clinical Services was Neuronetics’s largest segment in fiscal 2025, bringing in $86.98M of $149.16M (58%).
| Statement Business Segments | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Medical Device | $65.21M | $71.35M | $70.45M | $62.18M |
| Clinical Services | — | — | $4.45M | $86.98M |
| Total | $65.21M | $71.35M | $74.89M | $149.16M |
Neuronetics brought in $149.16M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $233.03M it reports by concentration risk type, so these segments do not cover all of its revenue. Clinical Services was the largest at $86.98M (58.3%), ahead of Medical Device at $62.18M (41.7%).
Compared with fiscal 2024, Clinical Services grew 1,856.7% to $86.98M, while Medical Device fell 11.7% to $62.18M.
Neuronetics began breaking out Clinical Services in fiscal 2024, when it brought in $4.45M.
Neuronetics (STIM) reports its revenue by concentration risk type, by geography and by statement business segments. In fiscal 2025, Service was its largest revenue line, bringing in $86.98M (37.3% of the total), followed by Clinic Revenue at $86.98M (37.3%).
Service was Neuronetics' largest revenue line in fiscal 2025, bringing in $86.98M, or 37.3% of the $233.03M total across its five revenue lines.
U.S was Neuronetics' largest region in fiscal 2025, bringing in $86.98M, or 98.6% of the $88.25M total across its two regions.
Clinical Services was Neuronetics' largest segment in fiscal 2025, bringing in $86.98M, or 58.3% of the $149.16M total across its two segments.
Among Neuronetics' revenue lines that make up at least 2% of revenue, Service grew fastest in fiscal 2025, up 1,856.7% from $4.45M to $86.98M.
Every figure comes from Neuronetics' annual financial filings, as reported. Each line keeps the name Neuronetics gives it, and years follow its fiscal calendar.
Neuronetics' revenue by concentration risk type goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.